{"product_id":"targeted-medicines-for-pediatric-low-grade-glioma-what-families-should-know-about-mapk-inhibitor-therapy","title":"Targeted Medicines for Pediatric Low-Grade Glioma: What Families Should Know About MAPK Inhibitor Therapy","description":"\u003cp\u003ePediatric low-grade glioma (pLGG), a slow-growing brain tumor, is the most common brain tumor of childhood, and roughly 7 in 10 of these tumors are driven by a single overactive growth pathway called MAPK. For decades, chemotherapy was the standard treatment when surgery could not be done, but many patients relapsed. Newer daily oral medicines called MAPK inhibitors now offer an effective and better-tolerated second-line option, and some are moving toward first-line use. This guide explains how these targeted drugs work, what side effects families should watch for, how doctors track tumor response, and why access matters for children around the world.\u003c\/p\u003e\n\n\u003ch1\u003eTargeted Medicines for Pediatric Low-Grade Glioma: What Families Should Know About MAPK Inhibitor Therapy\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eUnderstanding Pediatric Low-Grade Glioma (pLGG)\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#standard\"\u003eCurrent Standard Therapy: Surgery, Chemotherapy, and Radiation\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#mapk-basics\"\u003eWhat Are MAPK Inhibitors?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#drugs\"\u003eThe Drugs at a Glance: Doses and Results\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#side-effects\"\u003eManaging Side Effects of MAPK Inhibitors\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#monitoring\"\u003eHow Doctors Monitor Tumor Response\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients and Families\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What We Still Don't Know\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients and Caregivers\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003ePediatric low-grade glioma is the most common childhood brain tumor; about 70% are driven by the MAPK pathway.\u003c\/li\u003e\n\u003cli\u003eBRAF inhibitors are used only for BRAF V600E-mutant tumors, not fusions, where they may cause paradoxical growth.\u003c\/li\u003e\n\u003cli\u003eDabrafenib plus trametinib improved progression-free survival versus chemotherapy in BRAF V600E-mutant low-grade glioma.\u003c\/li\u003e\n\u003cli\u003eMEK inhibitors like selumetinib and trametinib are oral options, often used off-label as second-line therapy.\u003c\/li\u003e\n\u003cli\u003eSide effects include skin toxicity, heart and eye effects; growth arrest is specific to tovorafenib and reversible.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eUnderstanding Pediatric Low-Grade Glioma (pLGG)\u003c\/h2\u003e\n\n\u003cp\u003ePediatric low-grade gliomas are the most common brain tumors in children. They make up \u003cstrong\u003e30–40% of all pediatric central nervous system tumors\u003c\/strong\u003e, meaning 3 to 4 of every 10 childhood CNS tumors are pLGG.\u003c\/p\u003e\n\n\u003cp\u003e\"Low-grade\" means these tumors grow slowly, but they still cause serious problems depending on where they sit in the brain. The term pLGG actually covers many different tumor types. Each type has its own look under the microscope and its own genetic fingerprint.\u003c\/p\u003e\n\n\u003cp\u003eThe 2021 World Health Organization (WHO) classification system groups these tumors into three categories:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\u003cstrong\u003ePediatric-type diffuse low-grade gliomas\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eCircumscribed astrocytic gliomas\u003c\/strong\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003cstrong\u003eGlioneuronal and neuronal tumors\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe most common single type is \u003cstrong\u003epilocytic astrocytoma (PA)\u003c\/strong\u003e. It accounts for 10–15% of all brain tumors in children and about 5% of brain tumors in adults.\u003c\/p\u003e\n\n\u003cp\u003eNearly 70% of pLGGs share a common biological driver. They carry mutations in one genetic pathway, the \u003cstrong\u003eRAS-RAF-MAPK pathway\u003c\/strong\u003e (a chain of proteins inside cells that controls growth and division). Because of this, researchers often call pLGG a \"single pathway disease.\"\u003c\/p\u003e\n\n\u003cp\u003eLocation often matches the genetic driver. For example, \u003cstrong\u003epleomorphic xanthoastrocytomas\u003c\/strong\u003e usually form in the supratentorial area (upper part of the brain) and carry a specific mutation called \u003cstrong\u003eBRAF V600E\u003c\/strong\u003e. Meanwhile, pilocytic astrocytomas more often carry \u003cstrong\u003eBRAF fusions\u003c\/strong\u003e (where the BRAF gene joins with another gene) and grow in the posterior fossa (back of the brain) or along the optic pathway (the visual nerves).\u003c\/p\u003e\n\n\u003cp\u003epLGG also commonly occurs in children with \u003cstrong\u003eneurofibromatosis type 1 (NF1)\u003c\/strong\u003e, a genetic condition that raises tumor risk. Optic pathway gliomas occur in \u003cstrong\u003e15–20% of NF1 patients\u003c\/strong\u003e. Children with NF1 also face a higher risk of other RAS-pathway tumors, including plexiform neurofibromas (nerve-sheath tumors), brainstem gliomas, and diffuse astrocytomas.\u003c\/p\u003e\n\n\u003ch2 id=\"standard\"\u003eCurrent Standard Therapy: Surgery, Chemotherapy, and Radiation\u003c\/h2\u003e\n\n\u003cp\u003eSurgery is the first-line treatment for symptomatic pLGG when possible. However, more than half of these tumors — over 50% — are located where surgery is not safe or feasible. These include tumors in the diencephalon (deep brain structures), brainstem, optic pathway, or spinal cord. In those cases, surgery may be limited to a biopsy or partial removal, or it may not be offered at all.\u003c\/p\u003e\n\n\u003cp\u003eFor inoperable tumors, treatment choice depends on symptoms. Tumors in the optic pathway or brainstem often need urgent therapy to preserve vision or relieve neurological symptoms.\u003c\/p\u003e\n\n\u003cp\u003eChemotherapy remains standard of care for inoperable or residual pLGG. It works well and is tolerated by children of all ages, including the very young. The two most common regimens are \u003cstrong\u003ecarboplatin plus vincristine\u003c\/strong\u003e or \u003cstrong\u003esingle-agent vinblastine\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eOutcomes with chemotherapy are good but imperfect:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5-year overall survival (OS)\u003c\/strong\u003e — the chance of being alive 5 years after diagnosis — is \u003cstrong\u003e86–94%\u003c\/strong\u003e in recent studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e5-year progression-free survival (PFS)\u003c\/strong\u003e — the chance the tumor has not grown 5 years later — is less favorable at \u003cstrong\u003e42–45%\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eChildren with NF1 do somewhat better, with 5-year PFS of \u003cstrong\u003e69–85%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eChemotherapy side effects include suppression of blood cell production (myelosuppression), gastrointestinal problems, and peripheral nerve damage affecting sensation and movement (peripheral sensory and motor neuropathy). These effects are generally manageable. However, \u003cstrong\u003eallergic reactions to carboplatin occur in up to 8–20% of patients\u003c\/strong\u003e receiving carboplatin plus vincristine.\u003c\/p\u003e\n\n\u003cp\u003eRadiation therapy is very effective against pLGG. In the HIT-LGG-1996 trial, radiation achieved better 10-year progression-free survival than conventional chemotherapy (\u003cstrong\u003e62% versus 42%\u003c\/strong\u003e). Yet doctors largely avoid radiation in sporadic pLGG, and almost always avoid it in NF1-associated pLGG. The reason is the risk of serious late effects, including:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eSecondary (new) malignancies\u003c\/li\u003e\n  \u003cli\u003eNeurocognitive impairment\u003c\/li\u003e\n  \u003cli\u003eHormonal dysfunction\u003c\/li\u003e\n  \u003cli\u003eGrowth delay\u003c\/li\u003e\n  \u003cli\u003eVasculopathy and cerebrovascular injury (blood vessel damage in the brain)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRegardless of which upfront therapy is used, unresectable pLGG recurs in nearly \u003cstrong\u003e50% of patients\u003c\/strong\u003e after first-line treatment. Many children need episodic treatment throughout childhood and adolescence during periods of disease progression.\u003c\/p\u003e\n\n\u003cp\u003eExperts now view multiply recurrent pLGG like a chronic condition. The approach focuses on periodic flare-ups and symptoms. Overall survival stays excellent despite the less favorable PFS. The current goal of research is to find agents that produce durable responses and reduce the burden of treatment.\u003c\/p\u003e\n\n\u003cp\u003eMAPK inhibitors — targeted drugs that block RAF and MEK proteins — may fill that need.\u003c\/p\u003e\n\n\u003ch2 id=\"mapk-basics\"\u003eWhat Are MAPK Inhibitors?\u003c\/h2\u003e\n\n\u003cp\u003eMutations in the \u003cstrong\u003eBRAF oncogene\u003c\/strong\u003e (a gene that helps control cell growth) are among the most common genetic changes found in cancer. These changes keep the BRAF protein permanently switched on. That drives downstream signaling through MEK and ERK proteins, pushing tumor growth and proliferation.\u003c\/p\u003e\n\n\u003cp\u003eBRAF can be altered in two main ways:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBRAF V600E mutations:\u003c\/strong\u003e A single \"hotspot\" change (Val600Glu) makes the BRAF protein act as a lone monomer to drive ERK signaling.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBRAF fusions:\u003c\/strong\u003e The BRAF gene rearranges and pairs with a fusion partner. The rearranged protein forms a dimer (a two-part complex) that keeps signaling active on its own, independent of normal RAS control.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAmong the fusions, \u003cstrong\u003eKIAA1549::BRAF\u003c\/strong\u003e is the most common. It appears in \u003cstrong\u003e70–80% of pilocytic astrocytomas\u003c\/strong\u003e and in \u003cstrong\u003e30–40% of all pLGGs\u003c\/strong\u003e. New drugs that target this widespread fusion are highly sought after.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBRAF inhibitors\u003c\/strong\u003e (like vemurafenib and dabrafenib) were among the first targeted agents tested in pLGG. They showed remarkable success in BRAF V600E-altered tumors. But surprisingly, tumors with KIAA1549::BRAF fusions grew paradoxically when treated with these drugs — a biological phenomenon now well understood at the molecular level.\u003c\/p\u003e\n\n\u003cp\u003eBecause of that risk, \u003cstrong\u003eBRAF inhibitors are now used only in patients with BRAF V600E mutations, and they are contraindicated (not permitted) in patients with BRAF fusions.\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eDabrafenib was later tested in combination with the MEK inhibitor trametinib as first-line therapy for BRAF V600E-altered low-grade glioma. The combination improved progression-free survival dramatically compared with standard chemotherapy: \u003cstrong\u003ePFS was 20.1 months versus 7.4 months (hazard ratio, 0.31)\u003c\/strong\u003e. In plain terms, patients on the targeted combination had about a two-thirds lower risk of tumor progression during the study period. The combination also had a superior safety profile.\u003c\/p\u003e\n\n\u003cp\u003eThese results changed clinical practice:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eIn \u003cstrong\u003e2022\u003c\/strong\u003e, the FDA granted accelerated approval to the dabrafenib\/trametinib combination for progressive or metastatic solid tumors with BRAF V600E mutations.\u003c\/li\u003e\n  \u003cli\u003eIn \u003cstrong\u003e2023\u003c\/strong\u003e, the FDA approved the same combination as \u003cstrong\u003efirst-line treatment for pediatric patients age 1 and older\u003c\/strong\u003e who have pLGG with a BRAF V600E mutation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMEK inhibitors\u003c\/strong\u003e, including selumetinib, trametinib, mirdametinib, binimetinib, and cobimetinib, work one step downstream. They block MEK, the kinase protein that BRAF activates. Several have been studied in children with pLGG, with safety and efficacy data in recurrent pLGG and in NF1-associated pLGG.\u003c\/p\u003e\n\n\u003cp\u003eSelumetinib is now being tested against standard chemotherapy in two phase 3 trials for newly diagnosed pLGG, both with and without NF1 (NCT03871257 and NCT04166409). Because selumetinib and trametinib can be prescribed off-label today, they are frequently used in the real world as second-line therapy.\u003c\/p\u003e\n\n\u003ch2 id=\"drugs\"\u003eThe Drugs at a Glance: Doses and Results\u003c\/h2\u003e\n\n\u003cp\u003eThese are the targeted agents with published phase 2 trial data in pLGG and favorable toxicity profiles. Doses are provided so families can recognize them; actual dosing is always individualized by the care team.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDabrafenib (BRAF inhibitor)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDose: Children under 12 years: 2.625 mg\/kg twice daily. Age 12 and older: 2.25 mg\/kg twice daily. Maximum 150 mg per dose.\u003c\/li\u003e\n  \u003cli\u003eForm: Oral capsule or dispersible tablet.\u003c\/li\u003e\n  \u003cli\u003eEvidence: 47% overall response rate (ORR) when combined with trametinib in BRAF V600E-mutant pLGG.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eVemurafenib (BRAF inhibitor)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDose: 550 mg\/m² twice daily (maximum 960 mg per dose).\u003c\/li\u003e\n  \u003cli\u003eForm: Oral tablet.\u003c\/li\u003e\n  \u003cli\u003eEvidence: Phase 1 data showed a 32% overall response rate (ORR) in BRAF V600E-mutant pLGG.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBinimetinib (MEK1\/2 inhibitor)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDose: 32 mg\/m² twice daily (maximum 45 mg per dose).\u003c\/li\u003e\n  \u003cli\u003eForm: Oral tablet.\u003c\/li\u003e\n  \u003cli\u003eEvidence: 43% partial response rate in NF1-related tumors; 50% partial response in pLGG with BRAF fusions; 69% in sporadic pLGG without BRAF alterations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCobimetinib (MEK1\/2 inhibitor)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDose: 0.8 mg\/kg tablet or 1.0 mg\/kg suspension daily on a 3-weeks-on, 1-week-off schedule (maximum 60 mg per dose).\u003c\/li\u003e\n  \u003cli\u003eForm: Oral tablet or suspension.\u003c\/li\u003e\n  \u003cli\u003eEvidence: Phase 1\/2 data showed 5% partial response and 59% stable disease.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMirdametinib (MEK1\/2 inhibitor)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDose: 2 mg\/m² twice daily, 3 weeks on and 1 week off (maximum 4 mg per dose).\u003c\/li\u003e\n  \u003cli\u003eForm: Oral capsule or dispersible tablet. It penetrates the brain well.\u003c\/li\u003e\n  \u003cli\u003eEvidence: 52% ORR in plexiform neurofibroma (phase 2b); 63% ORR in pLGG (phase 1\/2). So far, 12 of 19 patients (63%) achieved objective responses — 1 major, 6 partial, and 5 minor. The phase 2 portion is ongoing, including newly diagnosed patients and those with prior MEK inhibitor exposure (NCT04923126).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSelumetinib (MEK1\/2 inhibitor)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDose: 25 mg\/m² twice daily (maximum 50 mg per dose).\u003c\/li\u003e\n  \u003cli\u003eForm: Oral capsule.\u003c\/li\u003e\n  \u003cli\u003eEvidence: In a phase 1 trial of children with recurrent pLGG, 20% had sustained partial response. In a phase 2 trial, \u003cstrong\u003e36–40% achieved sustained partial response\u003c\/strong\u003e. Two-year PFS was \u003cstrong\u003e70% in BRAF-altered, non-NF1 pLGG\u003c\/strong\u003e and \u003cstrong\u003e96% in children with germline NF1\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eIn NF1-associated plexiform neurofibromas, response rates were around \u003cstrong\u003e70%\u003c\/strong\u003e, and the FDA approved selumetinib for that indication.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTrametinib (MEK1\/2 inhibitor)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDose: Under 6 years: 0.032 mg\/kg daily. Age 6 and older: 0.025 mg\/kg daily. Maximum 2 mg per dose.\u003c\/li\u003e\n  \u003cli\u003eForm: Oral tablet or suspension.\u003c\/li\u003e\n  \u003cli\u003eEvidence: 61% ORR in plexiform neurofibroma; 47% ORR when combined with dabrafenib in BRAF V600E-mutant pLGG. Retrospective studies support single-agent activity. Interim phase 2 results in pLGG showed roughly \u003cstrong\u003e47% overall response rate\u003c\/strong\u003e (complete, partial, or minor response), and a \u003cstrong\u003e60% response rate by volumetric assessment\u003c\/strong\u003e in NF1-associated plexiform neurofibroma.\u003c\/li\u003e\n  \u003cli\u003eApproval context: FDA-approved in 2013 for adult BRAF V600E melanoma; used commonly off-label in children as molecularly guided therapy. A large prospective trial is ongoing (NCT03363217).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTovorafenib (Type II RAF inhibitor)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eDose: 380 mg\/m² taken orally once weekly.\u003c\/li\u003e\n  \u003cli\u003eForm: Oral tablet or suspension. It targets both mutant and normal (wild-type) A-Raf, B-Raf, and C-Raf proteins and can block RAF dimers, meaning it works against BRAF fusions.\u003c\/li\u003e\n  \u003cli\u003eEvidence: Among 137 patients with BRAF-altered relapsed or refractory pLGG, the ORR was \u003cstrong\u003e51% by RAPNO criteria\u003c\/strong\u003e and \u003cstrong\u003e67% by RANO-HGG criteria\u003c\/strong\u003e (the primary endpoint). Twelve patients (17%) had complete responses. The median duration of response was \u003cstrong\u003e13.8 months\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eThese patients were heavily pretreated: they entered the trial after a median of \u003cstrong\u003ethree prior lines of therapy\u003c\/strong\u003e, and 61% had already received a MEK and\/or BRAF inhibitor.\u003c\/li\u003e\n  \u003cli\u003eThe FDA granted tovorafenib \u003cstrong\u003eaccelerated approval for recurrent or refractory pLGG in 2024\u003c\/strong\u003e. It is now being compared with standard chemotherapy (single-agent vinblastine or carboplatin\/vincristine) in newly diagnosed RAF-altered pLGG.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"side-effects\"\u003eManaging Side Effects of MAPK Inhibitors\u003c\/h2\u003e\n\n\u003cp\u003eMAPK inhibitor side effects in children are now well described. The most common treatment-related effects involve the skin, gastrointestinal system, eyes, and heart.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSkin toxicity is the most frequent issue.\u003c\/strong\u003e Rashes can be eczematous (dry, itchy, flaky) or acneiform (acne-like). Patients may also develop \u003cstrong\u003eparonychia\u003c\/strong\u003e (painful inflammation around the fingernails or toenails) and hair color changes. Some patients develop wound complications.\u003c\/p\u003e\n\n\u003cp\u003eConsensus guidelines from groups including a Children's Tumor Foundation advisory board recommend prevention strategies:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eApply moisturizers and emollients regularly to maintain a healthy skin barrier.\u003c\/li\u003e\n  \u003cli\u003eUse sun protection.\u003c\/li\u003e\n  \u003cli\u003eTake bleach baths to reduce skin bacteria, prevent infectious complications, and ease itching.\u003c\/li\u003e\n  \u003cli\u003eFor adolescent patients, topical antibiotics and low-dose topical steroids help prevent facial acne in the \"T zone\" (forehead, nose, and chin).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOnce a rash appears, treatments include topical steroids, topical and oral antibiotics, and sometimes pausing the drug until the rash resolves or improves significantly.\u003c\/p\u003e\n\n\u003cp\u003eMild paronychia can be managed with frequent antiseptic soaks using chlorhexidine, plus topical antibiotics and topical steroids. Dermatology specialty care is recommended for severe or persistent cases.\u003c\/p\u003e\n\n\u003cp\u003eWound healing problems are less common but can be serious. Children who have surgery while on therapy — for example, placement of a ventricular shunt catheter or a central venous line — may heal more slowly. Pressure sores and skin ulcerations may also take longer to heal and require wound care expertise.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHeart effects are uncommon but monitored carefully.\u003c\/strong\u003e Published reports show low rates of cardiac toxicity in children. Still, most guidelines recommend routine echocardiograms (ECHO, an ultrasound of the heart) to check for an asymptomatic drop in ejection fraction (EF) — the heart's pumping strength.\u003c\/p\u003e\n\n\u003cp\u003eIn selumetinib trials, an EF decrease greater than 10% below the normal range occurred in one pediatric patient with NF1-associated pLGG and in \u003cstrong\u003e20 patients (40%) with non-NF1 associated pLGG\u003c\/strong\u003e. Most cases were found on routine screening without symptoms.\u003c\/p\u003e\n\n\u003cp\u003eConsensus recommendations for an asymptomatic EF drop beyond 10% of baseline:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eHold (pause) the MEK inhibitor.\u003c\/li\u003e\n  \u003cli\u003eIf the EF does not improve within 4 weeks off therapy, discontinue the drug altogether.\u003c\/li\u003e\n  \u003cli\u003eEF decrease is generally reversible after stopping or pausing the medication.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eRoutine ECHO monitoring is recommended after 1 month of therapy, then at regular intervals (for example, every 3–6 months). Notably, \u003cstrong\u003etovorafenib has not been linked to cardiac side effects\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eEye problems are rarely reported in children\u003c\/strong\u003e on published MAPK inhibitor studies. In adults, however, they can cause serious vision problems and even blindness. A class effect called \u003cstrong\u003eMEK inhibitor-associated retinopathy (MEKAR)\u003c\/strong\u003e affects anywhere from 5–90% of adult patients treated with MEK or BRAF inhibitors, depending on the report.\u003c\/p\u003e\n\n\u003cp\u003eSymptoms include blurry vision, floaters, and sensitivity to light (photophobia). In the most severe cases, retinal detachment or retinal vein occlusion can occur. In children, MEKAR is usually self-limited and may resolve whether or not the drug is stopped.\u003c\/p\u003e\n\n\u003cp\u003eBecause visual symptoms are usually noticeable, monitoring can be done clinically. However, most practitioners still recommend an ophthalmology (eye) exam early in therapy — usually after 1 month — and then every 3–6 months. The exam should include:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eVisual acuity testing (the standard eye chart) at minimum\u003c\/li\u003e\n  \u003cli\u003eVisual field testing for patients with optic pathway gliomas\u003c\/li\u003e\n  \u003cli\u003eConsideration of optical coherence tomography (OCT) to detect small retinal detachments\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAgain, tovorafenib has not been associated with retinal or eye-related side effects.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGrowth arrest is a distinctive side effect of tovorafenib.\u003c\/strong\u003e It has not been reported with the MEK inhibitors, and researchers do not yet know if it is a class effect of RAF inhibitors generally. Preliminary data show that children and adolescents stop growing while on tovorafenib, without advancement of bone age or premature closure of growth plates. This effect reverses once the drug is stopped. In fact, some patients resumed expected annual growth after therapy, and some even exceeded the expected average for their age after treatment.\u003c\/p\u003e\n\n\u003cp\u003eLong-term toxicity data are still immature. The drugs have not been commercially available long enough to know their late effects, which is a disadvantage compared with chemotherapy. However, off-therapy data are now being collected. Researchers are tracking organ function — especially heart and eye function — plus effects on growth, puberty, vision, and neurocognitive (thinking and learning) outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"monitoring\"\u003eHow Doctors Monitor Tumor Response\u003c\/h2\u003e\n\n\u003cp\u003eThe way doctors measure whether a pLGG is responding to MAPK inhibitor therapy has evolved. Early trials measured only the enhancing (bright) parts of the tumor on T1 post-contrast MRI scans. That approach was later changed, because enhancement patterns in pLGG can increase or decrease on their own without any treatment, do not reliably match true tumor volume, and do not predict outcome.\u003c\/p\u003e\n\n\u003cp\u003eInstead, modern trials measure tumor size on \u003cstrong\u003eT2\/FLAIR MRI sequences\u003c\/strong\u003e using two-dimensional measurements. These better capture the true extent of a low-grade glioma.\u003c\/p\u003e\n\n\u003cp\u003eThe phase 2 tovorafenib trial used the \u003cstrong\u003eResponse Assessment in Neuro-Oncology High-Grade Glioma (RANO-HGG) criteria\u003c\/strong\u003e as its primary endpoint, because those were the only criteria the FDA considered validated when the trial began. Secondary response assessments used the \u003cstrong\u003eRAPNO criteria\u003c\/strong\u003e (Response Assessment in Pediatric Neuro-Oncology Low-Grade Glioma) and the \u003cstrong\u003eRANO-LGG criteria\u003c\/strong\u003e — both of which were designed to avoid relying on enhancement changes.\u003c\/p\u003e\n\n\u003cp\u003eThe practical message for families: a \"stable\" or \"responding\" scan may look different depending on which criteria the radiology team applies, and lack of contrast enhancement does not mean the tumor is gone. Serial MRIs remain the backbone of monitoring.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients and Families\u003c\/h2\u003e\n\n\u003cp\u003eMAPK inhibitors bring practical advantages beyond their effectiveness. They are oral medications, and most — except selumetinib — come as a liquid formulation or dispersible tablet. That makes them ideal for young children and for patients who need feeding tubes (enteral nutrition).\u003c\/p\u003e\n\n\u003cp\u003eDosing schedules are convenient:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMEK and BRAF inhibitors are given once or twice daily, based on pharmacokinetic (drug absorption) studies.\u003c\/li\u003e\n  \u003cli\u003eSome MEK inhibitors require an empty stomach for the drug to absorb properly.\u003c\/li\u003e\n  \u003cli\u003eTovorafenib is unique: it is taken just once weekly, with or without food.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOral therapy can reduce the burden of clinic visits. Unlike weekly intravenous chemotherapy, MAPK inhibitors need fewer ambulatory visits for administration.\u003c\/p\u003e\n\n\u003cp\u003eThis matters most for children living in low-resource or geographically isolated areas. Ongoing studies are exploring whether MAPK inhibitors make sense as front-line therapy in limited populations, because the oral format may reduce \"financial toxicity\" — the cost and logistical strain of treatment — for families in low- and middle-income countries (LMIC).\u003c\/p\u003e\n\n\u003cp\u003eThe authors note that while Phase 3 trials are designed to answer which front-line therapy is safest and most effective, the use of MAPK inhibitors in the front-line setting is already being discussed for limited-resource populations.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What We Still Don't Know\u003c\/h2\u003e\n\n\u003cp\u003eThis review is based on the evidence available in early 2025, and important gaps remain.\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLong-term side effects are unknown.\u003c\/strong\u003e MAPK inhibitors have not been on the market long enough to define late effects, unlike decades of chemotherapy experience.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSome evidence is retrospective.\u003c\/strong\u003e Trametinib monotherapy, for example, is supported mainly by retrospective analyses while larger prospective trials continue.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFront-line phase 3 results are still pending.\u003c\/strong\u003e Trials comparing selumetinib with standard chemotherapy in newly diagnosed patients (NCT03871257 and NCT04166409) are ongoing, as is the trametinib trial (NCT03363217) and the mirdametinib study (NCT04923126).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe growth-arrest effect of tovorafenib may or may not be unique.\u003c\/strong\u003e Whether it is a class effect of other RAF inhibitors is unknown.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOff-label use carries uncertainty.\u003c\/strong\u003e Selumetinib and trametinib are prescribed off-label for pLGG while trials finish. Off-label use lacks the formal pediatric labeling, dosing refinements, and long-term safety surveillance that approval brings.\u003c\/li\u003e\n  \u003cli\u003eThe review was authored by specialists at major U.S. children's hospitals, and their perspective reflects high-resource settings, though they explicitly address limited-resource environments.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients and Caregivers\u003c\/h2\u003e\n\n\u003cp\u003eIf your child has a low-grade glioma, here is what this review suggests you discuss with your care team.\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about molecular testing.\u003c\/strong\u003e Knowing whether the tumor has a BRAF V600E mutation, a BRAF fusion like KIAA1549::BRAF, or an NF1 association directly determines which targeted drug is safe. BRAF inhibitors must be avoided in fusion-driven tumors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk whether a MAPK inhibitor is an option.\u003c\/strong\u003e For children who have relapsed after chemotherapy, MEK and RAF inhibitors are now established second-line (or later) options with meaningful response rates.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about clinical trials.\u003c\/strong\u003e Front-line phase 3 trials are actively enrolling children with newly diagnosed pLGG. Trial participation may offer access to new agents like tovorafenib before they become widely available.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStart skin care early.\u003c\/strong\u003e Moisturizers, sun protection, and bleach baths can prevent the most common side effects. Ask for a dermatology referral early if a rash or paronychia develops.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKeep scheduled heart and eye checks.\u003c\/strong\u003e Expect an ECHO after about 1 month of therapy and then every 3–6 months. Expect an ophthalmology exam on a similar schedule, especially for optic pathway tumors.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eWatch growth carefully on tovorafenib.\u003c\/strong\u003e Growth arrest appears reversible after stopping the drug, but height and bone age should be tracked.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDo not stop a drug without medical guidance.\u003c\/strong\u003e Ruff some side effects, pausing the drug is the right move — for example, a significant EF drop. But the decision to hold, resume, or stop must be made with the oncology team.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about practical access support.\u003c\/strong\u003e Oral, once-weekly options like tovorafenib reduce clinic visits. If travel, cost, or geography is a barrier, ask your team about patient assistance programs and telehealth options.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhy is the BRAF V600E mutation status of my child's tumor important before starting a MAPK inhibitor?\u003c\/h3\u003e\n\u003cp\u003eKnowing the genetic driver decides which targeted drug is safe. BRAF inhibitors like dabrafenib or vemurafenib work only for BRAF V600E-mutant tumors. In tumors with BRAF fusions, these drugs caused paradoxical tumor growth and are not permitted. MEK inhibitors, however, may still be an option for fusion-driven tumors. Ask your care team about molecular testing.\u003c\/p\u003e\n\u003ch3\u003eWhat are the common side effects of MEK inhibitors in children?\u003c\/h3\u003e\n\u003cp\u003eCommon side effects include skin rashes, dryness, paronychia around nails, hair color changes, and sometimes wound healing problems. Heart effects are uncommon, but doctors monitor heart function with echocardiograms. Eye problems are rarely reported in children, though routine eye exams are often recommended. Growth arrest has been reported only with tovorafenib, not MEK inhibitors.\u003c\/p\u003e\n\u003ch3\u003eMy child has a low-grade glioma with a BRAF V600E mutation. What treatment options are available?\u003c\/h3\u003e\n\u003cp\u003eFor BRAF V600E-altered low-grade glioma, the combination of dabrafenib plus trametinib improved progression-free survival significantly compared with standard chemotherapy in a clinical trial. In 2023, this combination was approved as first-line treatment for children aged 1 and older with this specific mutation. BRAF inhibitors are not used for fusion-driven tumors.\u003c\/p\u003e\n\u003ch3\u003eWhat does 'progression-free survival' mean for my child's tumor response?\u003c\/h3\u003e\n\u003cp\u003eProgression-free survival is the length of time after treatment that the tumor does not grow or progress. For example, in one study of BRAF V600E-mutant low-grade glioma, patients receiving dabrafenib plus trametinib had a median progression-free survival of 20.1 months versus 7.4 months with standard chemotherapy.\u003c\/p\u003e\n\u003ch3\u003eHow will doctors know if the MAPK inhibitor is working?\u003c\/h3\u003e\n\u003cp\u003eDoctors use serial MRI scans to monitor tumor response. Modern criteria measure tumor size on T2\/FLAIR sequences rather than relying only on contrast enhancement, because enhancement patterns can change without treatment. Stable or responding scans may look different depending on the criteria used. Your care team will interpret scans alongside your child's symptoms.\u003c\/p\u003e\n\u003ch3\u003eMy child has NF1 and a low-grade glioma. Is a MAPK inhibitor an option?\u003c\/h3\u003e\n\u003cp\u003eYes. Selumetinib, a MEK inhibitor, has shown response rates in children with NF1-associated low-grade glioma. In a phase 2 trial, sustained partial responses occurred in 36–40% of patients, and two-year progression-free survival was 96% in children with germline NF1. Selumetinib is also approved for NF1-related plexiform neurofibromas.\u003c\/p\u003e\n\u003ch3\u003eWhat is unique about tovorafenib compared with other MAPK inhibitors?\u003c\/h3\u003e\n\u003cp\u003eTovorafenib is a type II RAF inhibitor taken orally once weekly. It can block RAF dimers, making it effective against BRAF fusions. In a study of heavily pretreated relapsed or refractory low-grade glioma, overall response rate was 51% by RAPNO criteria. It is associated with reversible growth arrest in children.\u003c\/p\u003e\n\u003ch3\u003eMy child has a low-grade glioma and we were offered a MAPK inhibitor. Should we get a second opinion before starting?\u003c\/h3\u003e\n\u003cp\u003eA second opinion is worthwhile because the safe choice of targeted therapy depends on the tumor's exact genetic driver. BRAF inhibitors must not be used in tumors with BRAF fusions, while they are effective in BRAF V600E-mutant tumors. MEK inhibitors and newer RAF inhibitors are options for relapsed disease. A second opinion can confirm the molecular testing, review whether first-line chemotherapy is still preferred, and identify relevant clinical trials. Talk to your care team about sending pathology and MRI reports. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Crotty EE, Sato AA, Abdelbaki MS.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e Published in \u003cem\u003eFrontiers in Oncology\u003c\/em\u003e, Volume 15, article 1520316. Received October 31, 2024; accepted January 22, 2025; published February 11, 2025. DOI: 10.3389\/fonc.2025.1520316.\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individualized medical advice from your child's oncology team.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47576820154524,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"url":"https:\/\/diagnosticdetectives.kr\/products\/targeted-medicines-for-pediatric-low-grade-glioma-what-families-should-know-about-mapk-inhibitor-therapy","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}